H.C. Wainwright raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $70 from $69 and keeps a Buy rating on the shares following ...
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback